| |
Linagliptin,patients with events/total patients
|
Total comparators,patients with events/total patients
|
Cox HR (95% CI)
|
Incidence ratio (95% CI) CMH Test
|
|---|
|
Age (years)
|
|
≤50
|
5/1288
|
3/781
|
1.31 (0.31–5.58)
|
1.11 (0.47–2.63)
|
|
51 to <65
|
26/2817
|
26/1740
|
0.75 (0.43–1.30)
|
0.86 (0.52–1.41)
|
|
65 to 75
|
26/1418
|
29/902
|
0.78 (0.46–1.32)
|
0.84 (0.52–1.37)
|
|
≥75
|
3/324
|
4/189
|
0.63 (0.14–2.85)
|
0.88 (0.37–2.08)
|
|
Gender
|
|
Male
|
42/3183
|
50/2039
|
0.69 (0.45–1.04)
|
0.73 (0.49–1.08)
|
|
Female
|
18/2664
|
12/1573
|
1.22 (0.58–2.55)
|
1.27 (0.68–2.36)
|
|
Race
| | | | |
|
White
|
46/3405
|
49/2190
|
0.78 (0.52–1.17)
|
0.83 (0.56–1.23)
|
|
Black
|
4/215
|
1/200
|
3.92 (0.44–35.08)
|
1.50 (0.55–4.11)
|
|
Asian
|
10/2227
|
12/1222
|
0.59 (0.25–1.37)
|
0.76 (0.39–1.49)
|
|
Use of rescue medication
|
|
No
|
43/5080
|
46/2824
|
0.70 (0.46–1.07)
|
0.75 (0.50–1.12)
|
|
Yes
|
17/767
|
16/788
|
1.10 (0.56–2.19)
|
1.11 (0.64–1.91)
|
|
Investigator-reported hypoglycemia
|
|
No
|
48/5197
|
37/2918
|
0.86 (0.56–1.32)
|
0.97 (0.65–1.45)
|
|
Yes
|
12/650
|
25/694
|
0.79 (0.39–1.59)
|
0.78 (0.41–1.47)
|
|
Framingham 10-year CV risk score
|
|
≤15%
|
20/3797
|
24/2438
|
0.65 (0.36–1.18)
|
0.76 (0.45–1.29)
|
|
>15%
|
36/1433
|
38/1046
|
0.85 (0.54–1.35)
|
0.91 (0.60–1.39)
|
|
Baseline microalbuminuria
|
|
Normal (≤30 mg/g)
|
25/3610
|
25/2389
|
0.84 (0.48–1.47)
|
0.91 (0.56–1.50)
|
|
Elevated (>30 to ≤300 mg/g)
|
21/1248
|
21/771
|
0.75 (0.41–1.38)
|
0.83 (0.49–1.41)
|
|
High (>300 mg/g)
|
6/280
|
14/241
|
0.43 (0.16–1.11)
|
0.63 (0.31–1.26)
|
-
CI, confidence interval; CV, cardiovascular; HR, hazard ratio; CMH test, Cochran-Mantel-Haenszel test with treatment arm continuity correction.
